Stanford researchers have developed a general system to regulate the activities of specific proteins in mammalian cells using cell-permeable, synthetic molecules.
The Stanford team developed a groundbreaking approach to measure single molecules by precisely measuring the forces induced by the absorption of electromagnetic radiation.
Researchers in Professor Justin Sonnenburg's laboratory have developed genetic tools for manipulating Bacteroides, a prominent genus of gut bacteria, for imaging, diagnostics, and therapeutic drug delivery.
Stanford researchers have developed a novel mutant IL-9 receptor (IL9R) that significantly enhances the in vivo engraftment, expansion, and anti-tumor activity of adoptively transferred T cells.
Stanford researchers have developed an innovative method for efficiently generating robust lymphatic endothelial cells (iLECs) from human induced pluripotent stem cells (hiPSCs) through transcription factor-based protocols.
Stanford researchers have identified a small set of genes that can be used to diagnose active tuberculosis (TB), distinguish active TB from latent TB or other diseases, and predict progression from latent to active TB months before conventional tests.
Stanford scientists have designed a passive and active polarization-insensitive grating coupler that enables consistent fiber-to-chip light coupling regardless of input polarization state.
Researchers at Stanford have developed methods and compositions to provide inducible production of anti-inflammatory cytokines in mesenchymal stem cells (MSCs).
Stanford scientists have developed a plant-derived zinc protoporphyrin (ZnPP) produced from legume hemoglobin, a breakthrough therapy candidate for treating neonatal jaundice.
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
Researchers in the Wyss-Coray Lab are investigating a potential therapeutic antibody to treat lysosomal storage disorders and other related neurodegenerative diseases.
Stanford researchers have developed a novel RNA-targeting therapeutic platform using CRISPR-Cas13d to selectively degrade oncogenic mRNA associated with uveal melanoma (UM), an aggressive and treatment-resistant form of eye cancer.